Pacgen Life Science

Friday, May 12, 2017

Pacgen Gains Exclusive Global Commercial Rights to DermaMed™, DermaSoleil™ and Deserving Health™

Tuesday, Jan 24, 2017

Pacgen Announces New Markets for P113 Products

Friday, Nov 18, 2016

Pacgen Announces Stock Option Grant

Tuesday, Aug 16, 2016

PacGen Announces Progress on PAC-113 License

Tuesday, Feb 09, 2016

Pacgen Closes Private Placement Financing

Tuesday, Jan 19, 2016

Pacgen Announces Private Placement Financing and Election of New Director

Monday, Oct 19, 2015

Pacgen Announces New Appointments

Thursday, Jun 18, 2015

Pacgen Provides Update on Licensed Product, PAC-113

Thursday, Jan 30, 2014

Pacgen Enters into Agreement with General Biologicals Corporation

Thursday, Jan 30, 2014

Pacgen Appoints Interim Chief Executive Officer

Friday, Dec 07, 2012

Pacgen to exhibit at the AMP 2012 Annual Meeting in Long Beach, California

Wednesday, Jul 11, 2012

Pacgen Enters Into Exclusive Distribution Agreement With Arise Biotech Corporation

Monday, Apr 30, 2012

Pacgen Announces Name Change and New Trading Symbol

Tuesday, Mar 06, 2012

Pacgen Appoints Peter Sheu as COO

Monday, Jan 30, 2012

Pacgen Expands PAC-113 License

Wednesday, Jan 25, 2012

Pacgen Closes Private Placement Financing

Thursday, Jan 12, 2012

Pacgen Reports on Private Placement

Tuesday, Jan 10, 2012

Pacgen Reports on Annual and Special Shareholder Meeting

Tuesday, Oct 25, 2011

Pacgen Appoints Dr. Ming S. Liu as CEO

Friday, Sep 02, 2011

Pacgen Announces Private Placement Financing

Friday, Aug 05, 2011

Pacgen Reports Annual Financial Results

Monday, Apr 04, 2011

Pacgen Announces Issuance of Stock Options

Monday, Mar 14, 2011

Pacgen Announces Corporate Transformation

Tuesday, Mar 01, 2011

Pacgen Reports Third Quarter Financial Results

Tuesday, Nov 30, 2010

Pacgen Reports Second Quarter Financial Results

Sunday, Oct 10, 2010

Pacgen to Present at BIO InvestorForum 2007

Thursday, Oct 07, 2010

Pacgen Appoints Mr. John Hsuan as Director

Monday, Aug 30, 2010

Pacgen Reports First Quarter Financial Results

Wednesday, Jun 30, 2010

Pacgen Reports First Quarter Financial Results

Tuesday, Jun 08, 2010

Pacgen Completes Share Consolidation

Friday, May 28, 2010

Pacgen Closes Private Placement Financing

Monday, Apr 19, 2010

Pacgen Announces Private Placement Financing and Financial Restructuring

Tuesday, Mar 02, 2010

Pacgen Reports Third Quarter Financial Result

Wednesday, Jan 27, 2010

Pacgen Signs Research Collaboration Agreements

Monday, Nov 30, 2009

Pacgen Reports Second Quarter Financial Results

Tuesday, Sep 01, 2009

Pacgen Reports First Quarter Financial Results

Thursday, Aug 13, 2009

Pacgen Completes Acquisition of Xphase Pharmaceuticals

Friday, Jul 31, 2009

Pacgen Reports Fiscal 2009 Financial Results

Monday, Jun 08, 2009

Pacgen Signs Share Purchase Agreement to Acquire Xphase Pharmaceuticals

Tuesday, Apr 28, 2009

Pacgen to Acquire Xphase Pharmaceuticals

Tuesday, Apr 14, 2009

Pacgen Appoints New Director

Monday, Mar 30, 2009

Pacgen Announces Second Closing of Private Placement Financing

Tuesday, Mar 03, 2009

Pacgen Reports Third Quarter Financial Results

Tuesday, Feb 03, 2009

Pacgen Announces First Closing of Private Placement Financing

Friday, Jan 30, 2009

Pacgen Announces Private Placement Financing

Monday, Jan 12, 2009

Pacgen Announces Board Changes

Monday, Dec 29, 2008

Pacgen Terminates Letter of Intent with Medigen

Monday, Dec 01, 2008

Pacgen Reports Second Quarter Financial Results

Friday, Oct 31, 2008

Pacgen Appoints Interim Chief Executive Officer

Friday, Oct 24, 2008

Pacgen Enters Into a Letter of Intent with Medigen

Friday, Aug 29, 2008

Pacgen Reports First Quarter Financial Results

Tuesday, Jul 29, 2008

Pacgen Reports Fiscal 2008 Financial Results

Thursday, Jun 05, 2008

Pacgen Announces Positive Results from Phase IIb Dose-Ranging Trial of PAC-113

Tuesday, Apr 15, 2008

Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug

Monday, Mar 17, 2008

Pacgen Closes $903,000 Private Placement Financing

Friday, Feb 29, 2008

Pacgen Announces Third Quarter Financial Results

Wednesday, Nov 28, 2007

Pacgen Reports Second Quarter Financial Results

Monday, Nov 19, 2007

Pacgen Initiates a Phase IIB Clinical Trial for PAC-113

Tuesday, Nov 13, 2007

Pacgen Presents Research Data at ACCP on Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis

Thursday, Nov 01, 2007

Pacgen to Present at the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference

Wednesday, Oct 03, 2007

Pacgen to Present at BioContact Quebec 2007

Monday, Sep 24, 2007

Pacgen Announces Advances in PAC-113 Program

Tuesday, Aug 28, 2007

Pacgen Reports Fiscal 2008 First Quarter Results

Monday, Jul 30, 2007

Pacgen Reports Fiscal 2007 Fourth Quarter Results

Monday, May 07, 2007

Pacgen Announces Positive Results from Phase I/II Trial of Novel Anti-Fungal Drug.

Tuesday, Apr 17, 2007

Pacgen to Present at BioFinance 2007

Friday, Mar 30, 2007

Pacgen Builds on New Leadership and Updates Options Outstanding

Thursday, Mar 15, 2007

Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug

Tuesday, Mar 13, 2007

Pacgen Appoints Robert DuFresne as President & CEO

Thursday, Mar 01, 2007

Pacgen Reports Third Quarter Financial and Operating Results

Monday, Feb 12, 2007

Pacgen Appoints New Scientific Advisory Board Members

Thursday, Dec 07, 2006

Pacgen Announces Closing of its Initial Public Offering

Wednesday, Aug 30, 2006

Pacgen Biopharmaceuticals Files for Initial Public Offering

Monday, Jul 17, 2006

Pacgen Biopharmaceuticals Names Dr. Alan Moore and Mr. Kevin McGarry to the Board of Directors

Thursday, Apr 20, 2006

Pacgen Biopharmaceuticals Appoints Christina Yip as Chief Financial Officer

Wednesday, Apr 12, 2006

Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc.

Tuesday, Mar 07, 2006

Pacgen Biopharmaceuticals Receives Approval for Phase I/II Clinical Trial of PAC-113 for Oral Candidiasis

Monday, Apr 11, 2005

Pacgen Biopharmaceuticals Retains Dow Pharmaceutical Sciences for PAC-113 Phase I/II Human Clinical Trials

Tuesday, Mar 22, 2005

Pacgen Biopharmaceuticals In-Licenses Compounds for Oral Diseases from Demegen

Sunday, Oct 24, 2004

Pacgen Biopharmaceuticals Contracts Vancouver-based Syreon Corporation for its Phase I/II Clinical Trials of PAC-113 Mouthrinse in HIV Seropositive Patients with Oral Candidiasis